Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.50 |
| ▸ | ESR1 | P03372 | 4/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.44 |
| ▸ | PPARG | P37231 | 7/20 | 0.44 |
| ▸ | PPARD | Q03181 | 4/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA7 | P43166 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3533612 | 1.00 | PPARA (0.50) | PPARAESR1ESR2PPARGPPARD | |
| SCHEMBL6419166 | 0.86 | PPARA (0.54) | PPARAESR1ESR2PPARGPPARD | |
| SCHEMBL977513 | 0.86 | PPARA (0.54) | PPARAESR1ESR2PPARGPPARD | |
| SCHEMBL977514 | 0.86 | PPARA (0.54) | PPARAESR1ESR2PPARGPPARD | |
| SCHEMBL6736319 | 0.85 | ESR1 (0.46) | PPARAESR1ESR2CA12CA1 | |
| SCHEMBL3535227 | 0.84 | ESR1 (0.58) | PPARAESR1ESR2PPARGPPARD | |
| SCHEMBL3535230 | 0.84 | ESR1 (0.58) | PPARAESR1ESR2PPARGPPARD | |
| SCHEMBL6737977 | 0.84 | ESR1 (0.44) | PPARAESR1ESR2CA12CA1 | |
| SCHEMBL14501971 | 0.82 | PPARA (0.50) | PPARAESR1ESR2PPARGPPARD | |
| SCHEMBL27581576 | 0.82 | PPARA (0.70) | PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816385-B2 | Dimeric dicarboxylic acid derivatives, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-10-19 | — | — | US | disclosed |
| EP-1578716-A1 | DICARBOXYLIC ACID DERIVATIVES AS PPAR-AGONISTS | NOVO NORDISK A/S (DK) | 2005-09-28 | — | — | EP | disclosed |
| US-20040259950-A1 | Novel compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC | 2004-12-23 | — | — | US | disclosed |
| WO-2004056740-A1 | DICARBOXYLIC ACID DERIVATIVES AS PPAR-AGONISTS | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
| WO-2003024944-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF BICYCLIC ANTIDIABETIC COMPOUNDS | DR. REDDY'S LABORATORIES LTD. (IN) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259950-A1 | Novel compounds, their preparation and use | PPARG, PPARA, PPARD | PPARA 2/4885ESR1 1589/4885ESR2 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.